Comparison
9p13 Microdeletion Syndrome C4707097 vs 6 Phosphogluconate Dehydrogenase Deficiency C5543091
Clinical comparison between 9p13 Microdeletion Syndrome and 6 Phosphogluconate Dehydrogenase Deficiency for differential diagnosis and treatment planning.
9p13 Microdeletion Syndrome C4707097
A rare genetic condition caused by a deletion on chromosome 9p13. Affected individuals may have developmental delays, distinctive facial features, and growth concerns. Management involves supportive care from multiple specialists.
6 Phosphogluconate Dehydrogenase Deficiency C5543091
A rare enzyme deficiency affecting red blood cells that can cause anemia during oxidative stress. Symptoms may flare with certain medications or infections. Managed with avoidance of triggers.
6 comparison axes
Onset
9p13 Microdeletion Syndrome C4707097
Variable
6 Phosphogluconate Dehydrogenase Deficiency C5543091
Variable
Onset patterns differ
Severity
9p13 Microdeletion Syndrome C4707097
moderate
6 Phosphogluconate Dehydrogenase Deficiency C5543091
mild
Different severity levels
Chronic
9p13 Microdeletion Syndrome C4707097
Chronic
6 Phosphogluconate Dehydrogenase Deficiency C5543091
Chronic
Differing course
Communicable
9p13 Microdeletion Syndrome C4707097
No
6 Phosphogluconate Dehydrogenase Deficiency C5543091
No
Different transmission
Body System
9p13 Microdeletion Syndrome C4707097
congenital
6 Phosphogluconate Dehydrogenase Deficiency C5543091
metabolic
Same/different system
Category
9p13 Microdeletion Syndrome C4707097
genetic
6 Phosphogluconate Dehydrogenase Deficiency C5543091
metabolic
Different category
Bottom line
9p13-microdeletion-syndrome-C4707097 and 6-phosphogluconate-dehydrogenase-deficiency-C5543091 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 9p13 Microdeletion Syndrome C4707097 | 6 Phosphogluconate Dehydrogenase Deficiency C5543091 | Discriminating power |
|---|---|---|---|
| Developmental delay | May include developmental delay from early life | Not described as a typical presenting feature | High |
| Anemia with stress | Not described as oxidative hemolytic anemia | Anemia may flare with infection or certain medicines | High |
| Facial or growth features | Distinctive facial features and growth concerns may occur | Not described as a syndromic facial or growth disorder | Moderate |
When to favor each condition
Choose 9p13 Microdeletion Syndrome C4707097 when
Early developmental delay with growth concerns
A chromosomal evaluation is more relevant than an enzyme assay
High
Multiple congenital or dysmorphic findings
This pattern better fits a microdeletion than isolated hemolysis
Moderate
Suspected chromosomal imbalance
Genetic confirmation separates it from a metabolic enzyme finding
Moderate
Choose 6 Phosphogluconate Dehydrogenase Deficiency C5543091 when
Anemia after infection or a triggering medicine
This fits the described oxidative red-cell vulnerability
Moderate
Isolated anemia without a developmental syndrome
An enzyme deficiency is more plausible than a 9p13 deletion
Moderate
Planning avoidance of oxidative triggers
Management emphasizes trigger avoidance rather than developmental support alone
Moderate
How key tests differ
| Test | 9p13 Microdeletion Syndrome C4707097 | 6 Phosphogluconate Dehydrogenase Deficiency C5543091 | Interpretation |
|---|---|---|---|
| Chromosomal microarray | May identify a deletion involving 9p13 | Not expected to diagnose the enzyme deficiency | A deletion supports the left condition but does not exclude unrelated findings |
| Red-cell enzyme assay | Not the primary diagnostic test | May show reduced 6-phosphogluconate dehydrogenase activity; no cutoff is established here | An abnormal result requires hematology review and is not alone a complete diagnosis |
| Hemolysis studies | No specific hemolysis pattern is established | Markers may be abnormal during a symptomatic episode | Normal interval testing does not necessarily exclude episodic susceptibility |
Prognosis comparison
9p13 Microdeletion Syndrome C4707097
- Outcome
- Usually a chronic congenital condition with variable developmental and growth needs
- Factors
- Deletion extent, associated findings, and supportive care; specifics are not established
6 Phosphogluconate Dehydrogenase Deficiency C5543091
- Outcome
- Often mild between episodes, with possible anemia during oxidative stress
- Factors
- Trigger exposure, infections, and individual enzyme effect; frequency is not established
Time frame: Both are generally lifelong, with variable courses
Mortality and a uniform prognosis cannot be inferred from these sparse descriptions
Complications comparison
| Complication | Presentation |
|---|---|
| Developmental needs | Learning or developmental support may be needed Not described as a core complication Needs vary and should be assessed individually |
| Hemolytic anemia | Not established from the supplied description May occur with oxidative stress, infection, or certain medicines Episode frequency and severity are not established |
| Growth concerns | Growth concerns may occur Not described as a primary feature Growth should be monitored clinically without assuming a fixed course |
Patient education highlights
- HighDifferent conditions
One is a chromosomal deletion and the other a red-cell enzyme problem; they are not interchangeable diagnoses.
- HighTrigger awareness
For the enzyme deficiency, ask a clinician before new medicines and seek care for pallor, jaundice, or dark urine.
- MediumFollow-up
Microdeletion care is usually supportive and multidisciplinary. Exact outcomes are not established from these data.